14 results on '"Ma, Yi-Ling"'
Search Results
2. Hepatoma‐derived growth factor participates in concanavalin A‐induced hepatitis.
- Author
-
Wang, E‐Ming, Hu, Tsung‐Hui, Huang, Chao‐Cheng, Chang, Yi‐Chen, Yang, Shih‐Ming, Huang, Shih‐Tsung, Wu, Jian‐Ching, Ma, Yi‐Ling, Chan, Hoi‐Hung, Liu, Li‐Feng, Lu, Wen‐Bin, Kung, Mei‐Lang, Wen, Zhi‐Hong, Wang, Jui‐Chu, Ko, Chou‐Yuan, Tsai, Wei‐Lun, Chu, Tian‐Huei, and Tai, Ming‐Hong
- Published
- 2020
- Full Text
- View/download PDF
3. Design and application of condition monitoring for power transmission and transformation equipment based on smart grid dispatching control system.
- Author
-
Zhou, Gui-Ping, Luo, Huan-Huan, Ge, Wei-Chun, Ma, Yi-Ling, Qiu, Shi, and Fu, Li-Na
- Subjects
ELECTRIC power ,ELECTRIC power distribution grids ,ELECTRONIC data processing ,DATA analysis ,ELECTRIC industries - Abstract
With the increasing demand for power supply reliability and the transmission equipment is an important part of power generation, transmission and distribution engineering. In the study, which makes use of the advantages and the mechanism of responsibility area of D5000 system platform, in combination with other related applications, the system architecture, software architecture, and related main functions are designed for on-line monitoring application, and realised the comprehensive analysis of the on-line monitoring and collecting data of the transmission and transformation equipment, to obtain the characteristic parameters of the reaction state of the equipment, equipment fault diagnosis, analysis and judge the running state of the equipment, to fill the domestic electrical equipment condition monitoring and analysis system of electrical equipment and States unified data processing, analysis and judgment of technology gaps. The active maintenance system based on multi-dimension data analysis and fault prediction is formed from the state of equipment and referring to the running history of equipment state. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats.
- Author
-
Chu, Tian‐huei, Chan, Hoi‐hung, Hu, Tsung‐hui, Wang, E‐ming, Ma, Yi‐ling, Huang, Shih‐chung, Wu, Jian‐ching, Chang, Yi‐chen, Weng, Wen‐tsan, Wen, Zhi‐hong, Wu, Deng‐chyang, Chen, Yi‐ming Arthur, and Tai, Ming‐hong
- Subjects
CELECOXIB ,EPIRUBICIN ,DRUG efficacy ,LABORATORY rats ,LIVER cancer patients ,INHIBITION of cellular proliferation ,THERAPEUTICS - Abstract
Abstract: Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC). However, the outcome of HCC patients receiving epirubicin remains unsatisfactory. Moreover, our previous study indicated that celecoxib suppresses HCC progression and liver cancer stemness. This study evaluated the potential of celecoxib to serve as a complementary therapy during epirubicin treatment. Cell proliferation, apoptosis, invasiveness, and anchorage‐independent growth were analyzed in hepatoma cells. Therapeutic efficacy was validated in rat orthotopic Novikoff hepatoma. After animal sacrifice, the antitumor mechanism of celecoxib and epirubicin combined therapy was investigated by histological analysis. Celecoxib enhanced the cytotoxic activity of epirubicin in HCC cells by promoting apoptosis. Besides, celecoxib potentiated the antineoplastic function of epirubicin in inhibiting the invasiveness and anchorage‐independent growth of HCC cells. Ultrasound monitoring showed that combined therapy was more potent than either therapy alone in perturbing HCC progression. Consistently, the size and weight of dissected HCC tissues from rats receiving combined therapy were smallest among all groups. HCC treated with combined therapy exhibited the highest prevalence of apoptotic cells, which was accompanied by reduced proliferating and angiogenic activities in tumor tissues. Moreover, the expression levels of cancer stemness markers (CD44 and CD133) and drug transporter MDR‐1 were significantly diminished in rats receiving combined therapy. Besides, celecoxib treatment increased the infiltration of cytotoxic T lymphocytes (CTLs) and reduced the number of regulatory T cells (Tregs), tumor‐associated macrophages (TAMs), and the expression of immune checkpoint PD‐L1 in HCC tissues during epirubicin therapy. Celecoxib augmented the therapeutic efficacy while modulated cancer stemness and antitumor immunity. Thus, celecoxib may serve as complementary therapy to improve the outcome of patients with advanced HCC during epirubicin treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. The antimicrobial peptide tilapia piscidin 3 induces mitochondria-modulated intrinsic apoptosis of osteosarcoma cells.
- Author
-
Yuan, Chien-Han, Ma, Yi-Ling, Shih, Po-Chang, Chen, Chao-Ting, Cheng, Shu-Yu, Pan, Chieh-Yu, Jean, Yen-Hsuan, Chu, Yih-Min, Lin, Sung-Chun, Lai, Yu-Cheng, and Kuo, Hsiao-Mei
- Subjects
- *
APOPTOSIS , *REACTIVE oxygen species , *CELL survival , *NILE tilapia , *COMPACT bone , *OXYGEN consumption - Abstract
Osteosarcoma (OS) is the most common solid tumor of the bone that most often affects adolescents. The introduction of chemotherapy for the treatment of OS has largely improved the survival rates of patients with localized tumors. However, the 5-year survival rate of OS patients with relapsed or metastatic disease is only 10 to 20%. In this study, the antimicrobial peptide tilapia piscidin 3 (TP3), isolated from Nile tilapia (Oreochromis niloticus), was treated to OS MG63 cells. Our findings showed that TP3 concentration as low as 1 μM induced significant inhibition of cell viability and increased DNA fragmentation, as determined by the MTT and TUNEL assays, respectively. The protein expression levels of cleaved caspases 3/9 were increased. An in situ live-cell time-lapse video and cell tomographic microscopy images showed cellular blebbing, shrinkage, nuclear fragmentation, and chromatin condensation, with the formation of beaded apoptopodia. Moreover, there were significant increase in the production of TP3-induced mitochondrial and cellular reactive oxygen species (ROS), as well as down-regulated mitochondrial oxygen consumption and extracellular acidification rates. Additionally, TP3 enhanced mitochondrial fission, whereas fusion was attenuated. Furthermore, after administration of the mitochondria targeted antioxidant mitoTempo, TP3-induced ROS oxidant levels and alterations in cleaved caspases 3/9 expression were rescued. TP3 promoted mitochondria-modulated intrinsic apoptosis through the induction of ROS production, activation of caspases 3/9, and the down-regulation of mitochondrial oxygen consumption and extracellular acidification rates, suggesting that TP3 has potential as an innovative alternative for OS treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. α-Melanocyte-Stimulating Hormone Attenuates Neovascularization by Inducing Nitric Oxide Deficiency via MC-Rs/PKA/NF-κB Signaling.
- Author
-
Weng, Wen-Tsan, Wu, Chieh-Shan, Wang, Feng-Sheng, Wu, Chang-Yi, Ma, Yi-Ling, Chan, Hoi-Hung, Wu, Den-Chiung, Wu, Jian-Ching, Chu, Tian-Huei, Huang, Shih-Chung, and Tai, Ming-Hong
- Subjects
MELANOCYTES ,NITRIC oxide ,NEOVASCULARIZATION ,NF-kappa B ,MELANOCORTIN receptors - Abstract
α-melanocyte-stimulating hormone (α-MSH) has been characterized as a novel angiogenesis inhibitor. The homeostasis of nitric oxide (NO) plays an important role in neovascularization. However, it remains unclear whether α-MSH mitigates angiogenesis through modulation of NO and its signaling pathway. The present study elucidated the function and mechanism of NO signaling in α-MSH-induced angiogenesis inhibition using cultured human umbilical vein endothelial cells (HUVECs), rat aorta rings, and transgenic zebrafish. By Griess reagent assay, it was found α-MSH dose-dependently reduced the NO release in HUVECs. Immunoblotting and immunofluorescence analysis revealed α-MSH potently suppressed endothelial and inducible nitric oxide synthase (eNOS/iNOS) expression, which was accompanied with inhibition of nuclear factor kappa B (NF-κB) activities. Excessive supply of NO donor l-arginine reversed the α-MSH-induced angiogenesis inhibition in vitro and in vivo. By using antibody neutralization and RNA interference, it was delineated that melanocortin-1 receptor (MC1-R) and melanocortin-2 receptor (MC2-R) participated in α-MSH-induced inhibition of NO production and NF-κB/eNOS/iNOS signaling. This was supported by pharmaceutical inhibition of protein kinase A (PKA), the downstream effector of MC-Rs signaling, using H89 abolished the α-MSH-mediated suppression of NO release and eNOS/iNOS protein level. Therefore, α-MSH exerts anti-angiogenic function by perturbing NO bioavailability and eNOS/iNOS expression in endothelial cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain.
- Author
-
Bee, Youn-Shen, Ma, Yi-Ling, Chen, Jinying, Tsai, Pei-Jhen, Sheu, Shwu-Jiuan, Lin, Hsiu-Chen, Huang, Hu, Liu, Guei-Sheung, and Tai, Ming-Hong
- Subjects
- *
RETINAL degeneration , *NEOVASCULARIZATION , *PEPTIDES , *CALRETICULIN , *ENDOTHELIAL cells - Abstract
Choroidal neovascularization (CNV) is a key pathological feature of several leading causes of vision loss including neovascular age-related macular degeneration. Here, we show that a calreticulin anti-angiogenic domain (CAD)-like peptide 27, CAD27, inhibited in vitro angiogenic activities, including tube formation, migration of endothelial cells, and vascular sprouting from rat aortic ring explants. In a rat model of laser-induced CNV, we demonstrate that intravitreal injection of CAD27 significantly attenuated the formation of CNV lesions as measured via fundus fluorescein angiography and choroid flat-mounts (19.5% and 22.4% reductions at 10 μg and 20 μg of CAD27 injected, respectively). Similarly, the reduction of CNV lesions was observed in rats that had received topical applications of CAD27 (choroid flat-mounts: 17.9% and 32.5% reductions at 10 μg/mL and 20 μg/mL of CAD27 instilled, respectively). Retinal function was unaffected, as measured using electroretinography in both groups receiving interareal injection or topical applications of CAD27 for at least fourteen days. These findings show that CAD27 can be used as a potential therapeutic alternative for targeting CNV in diseases such as neovascular age-related macular degeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. α-Melanocyte-stimulating hormone inhibits angiogenesis through attenuation of VEGF/VEGFR2 signaling pathway.
- Author
-
Weng, Wen-Tsan, Huang, Shih-Chung, Ma, Yi-Ling, Chan, Hoi-Hung, Lin, Shih-Wei, Wu, Jian-Ching, Wu, Chang-Yi, Wen, Zhi-Hong, Wang, E-Ming, Wu, Chao-Liang, and Tai, Ming-Hong
- Subjects
- *
MSH (Hormone) , *NEOVASCULARIZATION , *VASCULAR endothelial growth factors , *CELLULAR signal transduction , *GENE therapy , *PROOPIOMELANOCORTIN - Abstract
Abstract: Background: Gene therapy of proopiomelanocortin, the precursor of α-melanocyte-stimulating hormone (α-MSH), suppresses the neovascularization in tumors. However, the roles of α-MSH in angiogenesis remain unclear. Methods: The influence of α-MSH on angiogenesis was evaluated by ex vivo rat aorta and in vivo, including transgenic zebrafish and chicken chorioallantoic membrane (CAM) assays. The effect of α-MSH on proliferation, matrix metalloproteinase (MMP) secretion, migration and tube formation was examined using human umbilical vein endothelial cells (HUVECs). The expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) was investigated by quantitative RT-PCR, immunoblot and immunofluorescent analysis. Antibodies' neutralization was employed to dissect the receptor(s) transmitting α-MSH signaling. Results: Application of α-MSH potently suppressed the microvessels sprouting in organotypic aortic rings. Besides, α-MSH perturbed the vessels development in zebrafish and chicken embryos. α-MSH (0.01–10nM) inhibited the MMP-2 secretion, migration and tube formation of HUVECs without affecting proliferation. Mechanistic studies unveiled α-MSH decreased the VEGF expression and release in HUVECs. Besides, α-MSH downregulated the VEGFR2 expression at transcriptional and translational levels. Importantly, α-MSH attenuated the Akt phosphorylation, but enhanced the expression of PTEN, endogenous antagonist of PI3K/Akt signaling. Expression analysis and antibody neutralization revealed that MC1-R and MC2-R participated in α-MSH-induced blockage of migration and VEGF/VEGFR2/Akt signaling. However, VEGF supply failed to reverse the anti-angiogenic function of α-MSH. Conclusions: α-MSH inhibits the physiological angiogenesis by attenuating VEGF/VEGFR2/Akt signaling in endothelial cells. General significance: α-MSH is a potent angiogenesis inhibitor targeting at endothelial VEGF/VEGFR2 signaling, which may have potential for therapeutic application. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
9. Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway
- Author
-
Kung, Mei-Lang, Tsai, Han-En, Hu, Tsung-Hui, Kuo, Hsiao-Mei, Liu, Li-Fen, Chen, San-Cher, Lin, Pey-Ru, Ma, Yi-Ling, Wang, E-Ming, Liu, Guei-Sheung, Liu, Jong-Kang, and Tai, Ming-Hong
- Subjects
- *
HEPATOCELLULAR carcinoma , *GROWTH factors , *PHOSPHATIDYLINOSITOL 3-kinases , *PROTEIN kinase B , *CANCER cell physiology , *METASTASIS , *CELL migration - Abstract
Abstract: Hepatoma-derived growth factor (HDGF) stimulates the migration, invasion and metastasis in several types of cancer cells. However, the mechanism underlying HDGF-stimulated migration remains unclear. In this study, we investigated the influence of HDGF on cytoskeleton remodeling and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway in non-transformed NIH/3T3 cells. Exogenous HDGF promoted the migration and the formation of dorsal ruffles and podosome rosettes. Besides, HDGF supply increased the PI3K expression and Akt phosphorylation in dose- and time-dependent manners. Application of LY294002, a PI3K inhibitor, attenuated the HDGF-induced migration, dorsal ruffles and podosome rosettes formation. Consistently, the HDGF-overexpressing NIH/3T3 transfectants exhibited significantly increased motility and elevated PI3K/Akt activities, which were repressed by LY294002 or adenovirus-mediated overexpression of endogenous PI3K antagonist, PTEN. In summary, HDGF elicits the activation of PI3K/Akt signaling cascade, thereby promoting cytoskeleton remodeling to stimulate cellular migration. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
10. Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathway.
- Author
-
Lin SW, Huang SC, Kuo HM, Chen CH, Ma YL, Chu TH, Bee YS, Wang EM, Wu CY, Sung PJ, Wen ZH, Wu DC, Sheu JH, and Tai MH
- Subjects
- Animals, Cell Movement drug effects, Cell Proliferation drug effects, Cells, Cultured, Human Umbilical Vein Endothelial Cells drug effects, Humans, Male, Matrix Metalloproteinase Inhibitors pharmacology, Neovascularization, Pathologic prevention & control, Rats, Rats, Sprague-Dawley, Signal Transduction drug effects, Zebrafish, Angiogenesis Inhibitors pharmacology, Anthozoa chemistry, Butanones pharmacology, Sulfones pharmacology, Vascular Endothelial Growth Factor A drug effects, Vascular Endothelial Growth Factor Receptor-2 drug effects
- Abstract
Background: WA-25 (dihydroaustrasulfone alcohol, a synthetic derivative of marine compound WE-2) suppresses atherosclerosis in rats by reducing neointima formation. Because angiogenesis plays a critical role in the pathogenesis of atherosclerosis, the present study investigated the angiogenic function and mechanism of WA-25., Methods: The angiogenic effect of WA-25 was evaluated using a rat aortic ring assay and transgenic zebrafish models were established using transgenic Tg(fli-1:EGFP)y1 and Tg(kdrl:mCherryci5-fli1a:negfpy7) zebrafish embryos. In addition, the effect of WA-25 on distinct angiogenic processes, including matrix metalloproteinase (MMP) expression, endothelial cell proliferation and migration, as well as tube formation, was studied using human umbilical vein endothelial cells (HUVECs). The effect of WA-25 on the endothelial vascular endothelial growth factor (VEGF) signaling pathway was elucidated using qRT-PCR, immunoblot analysis, immunofluorescence and flow cytometric analyses., Results: The application of WA-25 perturbed the development of intersegmental vessels in transgenic zebrafish. Moreover, WA-25 potently suppressed microvessel sprouting in organotypic rat aortic rings. Among cultured endothelial cells, WA-25 significantly and dose-dependently inhibited MMP-2/MMP-9 expression, proliferation, migration and tube formation in HUVECs. Mechanistic studies revealed that WA-25 significantly reduced the VEGF release by reducing VEGF expression at the mRNA and protein levels. In addition, WA-25 reduced surface VEGF receptor 2 (VEGFR2/Flk-1) expression by repressing the VEGFR2 mRNA level. Finally, an exogenous VEGF supply partially rescued the WA-25-induced angiogenesis blockage in vitro and in vivo., Conclusions: WA-25 is a potent angiogenesis inhibitor that acts through the down-regulation of VEGF and VEGFR2 in endothelial cells., General Significance: WA-25 may constitute a novel anti-angiogenic drug that acts by targeting endothelial VEGF/VEGFR2 signaling.
- Published
- 2015
- Full Text
- View/download PDF
11. A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells.
- Author
-
Ma YL, Lin SW, Fang HC, Chou KJ, Bee YS, Chu TH, Chang MC, Weng WT, Wu CY, Cho CL, and Tai MH
- Subjects
- Angiogenesis Inhibitors chemistry, Angiogenesis Inhibitors therapeutic use, Angiogenesis Inhibitors toxicity, Animals, Animals, Genetically Modified, Aorta, Carcinoma, Lewis Lung blood supply, Carcinoma, Lewis Lung drug therapy, Cell Movement drug effects, Down-Regulation drug effects, Drug Evaluation, Preclinical, Embryo, Nonmammalian blood supply, Embryo, Nonmammalian drug effects, Endothelium, Vascular enzymology, Endothelium, Vascular metabolism, Enzyme Induction drug effects, Human Umbilical Vein Endothelial Cells, Humans, Macrocyclic Compounds chemistry, Macrocyclic Compounds therapeutic use, Macrocyclic Compounds toxicity, Matrix Metalloproteinase 2 metabolism, Mice, Mice, Inbred C57BL, Morphogenesis drug effects, Naphthalenesulfonates chemistry, Naphthalenesulfonates therapeutic use, Naphthalenesulfonates toxicity, Neovascularization, Pathologic drug therapy, Zebrafish embryology, Angiogenesis Inhibitors pharmacology, Endothelium, Vascular drug effects, Macrocyclic Compounds pharmacology, Matrix Metalloproteinase 2 biosynthesis, Naphthalenesulfonates pharmacology, Neovascularization, Physiologic drug effects
- Abstract
Angiogenesis, the process of neovascularization, plays an important role in physiological and pathological conditions. ST104P is a soluble polysulfated-cyclo-tetrachromotropylene compound with anti-viral and anti-thrombotic activities. However, the functions of ST104P in angiogenesis have never been explored. In this study, we investigated the effects of ST104P in angiogenesis in vitro and in vivo. Application of ST104P potently suppressed the microvessels sprouting in aortic rings ex vivo. Furthermore, ST104P treatment significantly disrupted the vessels' development in transgenic zebrafish in vivo. Above all, repeated administration of ST104P resulted in delayed tumor growth and prolonged the life span of mice bearing Lewis lung carcinoma. Mechanistic studies revealed that ST104P potently inhibited the migration, tube formation and wound closure of human umbilical endothelial cells (HUVECs). Moreover, ST104P treatment inhibited the secretion and expression of matrix metalloproteinase-2 (MMP-2) in a dose-dependent manner. Together, these results suggest that ST104P is a potent angiogenesis inhibitor and may hold potential for treatment of diseases due to excessive angiogenesis including cancer.
- Published
- 2014
- Full Text
- View/download PDF
12. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
- Author
-
Chu TH, Chan HH, Kuo HM, Liu LF, Hu TH, Sun CK, Kung ML, Lin SW, Wang EM, Ma YL, Cheng KH, Lai KH, Wen ZH, Hsu PI, and Tai MH
- Subjects
- Animals, Apoptosis drug effects, Blotting, Western, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Celecoxib, Cell Proliferation drug effects, Cyclooxygenase 2 chemistry, Cyclooxygenase 2 genetics, Cyclooxygenase 2 metabolism, Dinoprostone metabolism, Disease Progression, Flow Cytometry, Fluorescent Antibody Technique, Humans, Hyaluronan Receptors metabolism, Immunoenzyme Techniques, Liver Neoplasms metabolism, Liver Neoplasms pathology, Male, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells metabolism, Neoplastic Stem Cells pathology, PPAR gamma genetics, PPAR gamma metabolism, PTEN Phosphohydrolase genetics, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, RNA, Messenger genetics, Rats, Rats, Sprague-Dawley, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, Transcriptional Activation, Tumor Cells, Cultured, Up-Regulation, Carcinoma, Hepatocellular drug therapy, Cyclooxygenase 2 Inhibitors pharmacology, Liver Neoplasms drug therapy, PTEN Phosphohydrolase metabolism, Pyrazoles pharmacology, Sulfonamides pharmacology
- Abstract
Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several types of cancer, including hepatocellular carcinoma (HCC). Here we show that celecoxib suppressed the self-renewal and drug-pumping functions in HCC cells. Besides, celecoxib depleted CD44+/CD133+ hepatic cancer stem cells (hCSC). Prostaglandin E2 (PGE2) and CD133 overexpression did not reverse the celecoxib-induced depletion of hCSC. Also, celecoxib inhibited progression of rat Novikoff hepatoma. Moreover, a 60-day celecoxib program increased the survival rate of rats with hepatoma. Histological analysis revealed that celecoxib therapy reduced the abundance of CD44+/CD133+ hCSCs in hepatoma tissues. Besides, the hCSCs depletion was associated with elevated apoptosis and blunted proliferation and angiogenesis in hepatoma. Celecoxib therapy activated peroxisome proliferator-activated receptor γ (PPARγ) and up-regulated PTEN, thereby inhibiting Akt and disrupting hCSC expansion. PTEN gene delivery by adenovirus reduced CD44/CD133 expression in vitro and hepatoma formation in vivo. This study suggests that celecoxib suppresses cancer stemness and progression of HCC via activation of PPARγ/PTEN signaling.
- Published
- 2014
- Full Text
- View/download PDF
13. Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats.
- Author
-
Bee YS, Sheu SJ, Ma YL, Lin HC, Weng WT, Kuo HM, Hsu HC, Tang CH, Liou JC, and Tai MH
- Subjects
- Animals, Aorta drug effects, Aorta pathology, Calreticulin adverse effects, Cell Line, Cell Movement drug effects, Choroidal Neovascularization physiopathology, Electroretinography, Endothelial Cells drug effects, Endothelial Cells physiology, Fluorescein Angiography, Humans, In Vitro Techniques, Male, Ophthalmic Solutions, Peptide Fragments adverse effects, Rats, Rats, Inbred BN, Rats, Sprague-Dawley, Recombinant Fusion Proteins administration & dosage, Recombinant Fusion Proteins adverse effects, Recombinant Proteins administration & dosage, Recombinant Proteins adverse effects, Retina drug effects, Retina physiopathology, Retinal Neovascularization diagnosis, Thioredoxins administration & dosage, Thioredoxins adverse effects, Angiogenesis Inhibitors administration & dosage, Calreticulin administration & dosage, Choroidal Neovascularization diagnosis, Choroidal Neovascularization etiology, Lasers, Peptide Fragments administration & dosage, Radiation Injuries complications
- Abstract
Purpose: Vasostatin 48 (VS48) is a peptide of 48 amino acids derived from calreticulin. This study aimed to investigate the effects of topical application of VS48 eyedrops on experimental choroidal neovascularization (CNV)., Methods: Recombinant VS48 was expressed and purified as a thioredoxin (TRX)-fused protein, TRX-VS48. The anti-angiogenic effects of TRX-VS48 were validated by migration and tube formation assays performed on cultured endothelial cells, and by rat aorta ring assays. CNV lesions were created in Brown Norway rats by laser-induced photocoagulation at day 1. After topical TRX-VS48 application for 21 days, the CNV lesions were monitored via either choroidal flat mounts on day 21 or by fluorescent angiography on days 21, 28, 35, and 42. CNV lesions were evaluated by histological analysis. The retinal function of animals was examined by electroretinogram (ERG) to evaluate the safety and therapeutic efficacy of TRX-VS48., Results: Application of TRX-VS48 inhibited the migration and tube formation of endothelial cells. TRX-VS48 inhibited the growth of sprouting vessels in aorta rings. ERG analysis revealed that topical TRX-VS48 application for 21 days had no effect on rat retinal functions. After CNV induction, topical TRX-VS48 application for 21 days significantly reduced the size of CNV, as assayed by flat mounts. Fluorescent angiography revealed that the CNV areas in TRX-VS48-treated eyes were significantly reduced compared with TRX-treated eyes on days 21, 28, 35, and 42. Histological analysis also revealed attenuated CNV lesions in TRX-VS48-treated eyes. Topical TRX-VS48 treatment significantly reversed the CNV-induced alterations in ERG parameters on day 35., Conclusions: Topical TRX-VS48 application suppressed laser-induced CNV in rats, thereby constituting a possible modality for ocular diseases due to excessive angiogenesis.
- Published
- 2010
14. Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.
- Author
-
Sheu SJ, Bee YS, Ma YL, Liu GS, Lin HC, Yeh TL, Liou JC, and Tai MH
- Subjects
- Administration, Topical, Animals, Cell Movement drug effects, Endothelial Cells drug effects, Endothelial Cells pathology, Fluorescein Angiography, Fluorescent Antibody Technique, Humans, Immunoblotting, Lasers, Neovascularization, Physiologic drug effects, Rats, Rats, Inbred BN, Retina drug effects, Angiogenesis Inhibitors pharmacology, Calreticulin pharmacology, Choroidal Neovascularization prevention & control, Peptide Fragments pharmacology
- Abstract
Purpose: Choroidal neovascularization (CNV) is the leading cause of blindness in patients with age-related macular degeneration (AMD). This study evaluated the inhibitory effect of vasostatin (VS), an endogenous angiogenesis inhibitor, on CNV., Methods: Anti-angiogenic activity of VS was evaluated in vitro by migration and tube formation assays in human umbilical vein endothelial cells (HUVECs). CNV lesions were induced in Brown Norway rats by fundus argon laser photocoagulation. Beginning one day after CNV induction, rats were treated with eye drops containing 1 microg/ml VS in PBS buffer for three times daily for 20 days. The extent of CNV was examined by flat mount analysis on day 24 or by fundus fluorescein angiography (FAG) on days 21, 28, 35, and 42, respectively. CNV lesions and choroidal vascularity were evaluated by histological analysis. The spatial distribution of topically applied VS in rat eyes was evaluated by immunoblot analysis., Results: VS inhibited migration and tube formation in HUVECs. Flat mount analysis revealed that, after laser-induced photocoagulation, topical VS application for 20 days significantly reduced CNV lesions. Moreover, serial FAG analysis indicated that a 20 day VS treatment significantly reduced CNV lesions on all subsequent days. Histological analysis revealed attenuated lesions, intact Bruch's membrane, and reduced choroidal vascularity in VS-treated eyes. Finally immunoblot analysis reveled VS expression in choroids., Conclusions: Topical VS application suppresses the progression of laser-induced CNV via angiogenesis inhibition and may constitute a therapeutic alternative for excessive neovascularization occurring with ocular diseases.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.